Medicare to Cover GLP-1 Weight-Loss Drugs Starting July 1
Older Americans gain Medicare access to GLP-1 drugs for obesity beginning July 1, with out-of-pocket costs capped at $50 a month.
For the first time in the program's history, Medicare beneficiaries who meet eligibility requirements will be able to access GLP-1 medications for weight loss — a class of drugs that has reshaped obesity treatment in recent years — starting July 1. The monthly cost to qualifying enrollees will be capped at $50, a significant reduction from the retail prices that have made these medications out of reach for many Americans without robust private insurance coverage.
The development marks a meaningful policy shift, given that Medicare had long been barred from covering weight-loss drugs regardless of clinical need. The expansion reflects growing medical consensus that obesity is a chronic disease warranting pharmaceutical treatment, not merely a lifestyle issue. For older adults, who disproportionately carry obesity-related conditions such as type 2 diabetes, heart disease, and mobility limitations, the coverage could translate into substantial health benefits over time.
Read more American Couple Left NYC, Bought Italian Home for $13,000 →
However, access to affordable GLP-1s is not without trade-offs that beneficiaries should weigh carefully. Side effects associated with this drug class — including nausea, gastrointestinal distress, and, notably, loss of lean muscle mass — carry particular relevance for older patients. Muscle loss is already an age-related concern, and combining that natural trajectory with the muscle-depleting effects of rapid weight reduction could increase the risk of frailty and falls, two leading threats to independence among seniors.
Financial advisers and physicians alike are likely to counsel Medicare enrollees to pair any GLP-1 regimen with resistance exercise and adequate protein intake to mitigate muscle loss — though that clinical guidance extends beyond what the coverage policy itself mandates. Beneficiaries should consult their doctors about whether they meet the qualifying criteria and how to structure a treatment plan that accounts for age-specific risks alongside the clear metabolic benefits these medications can provide.
Continue reading at MarketWatch.com
